CV Sciences (CVSI) Operating Income (2012 - 2026)
CV Sciences (CVSI) reported Operating Income of -$318000.0 for Q1 2026, down 2990.91% on a YoY basis from $11000.0 in Q1 2025, and down 324.0% sequentially from -$75000.0 in Q4 2025.
CV Sciences (CVSI) Operating Income (2012 - 2026) Analysis & Trends
CV Sciences (CVSI) has 15 years of Operating Income data on file, last reported at -$318000.0 in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 2990.91% year-over-year to -$318000.0; the trailing twelve-month figure through Mar 2026 stood at -$799000.0 (up 48.75% YoY), and the FY2025 full-year result was -$470000.0, up 78.54% from the prior year.
- Operating Income retreated to -$318000.0 in Q1 2026, from -$75000.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $5.8 million in Q1 2023 to a low of -$2.3 million in Q2 2022.
- A 5-year average of -$380294.1 and a median of -$583000.0 in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 480.33% in 2023 and tumbled 2990.91% in 2026, its largest moves.
- Tracing CVSI's Operating Income over 5 years: stood at -$2.1 million in 2022, then soared by 58.16% to -$889000.0 in 2023, then increased by 27.33% to -$646000.0 in 2024, then surged by 88.39% to -$75000.0 in 2025, then plunged by 324.0% to -$318000.0 in 2026.
- Business Quant data shows CVSI's Operating Income at -$318000.0 in Q1 2026, -$75000.0 in Q4 2025, and -$275000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -318,000.00 |
| Dec 31, 2025 | -75,000.00 |
| Sep 30, 2025 | -275,000.00 |
| Jun 30, 2025 | -131,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Sep 30, 2024 | -341,000.00 |
| Jun 30, 2024 | -583,000.00 |
| Mar 31, 2024 | -620,000.00 |
| Dec 31, 2023 | -889,000.00 |
| Sep 30, 2023 | -437,000.00 |
| Jun 30, 2023 | -1.08 Mn |
| Mar 31, 2023 | 5.76 Mn |
| Dec 31, 2022 | -2.13 Mn |
| Sep 30, 2022 | -892,000.00 |
| Jun 30, 2022 | -2.32 Mn |
| Mar 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -8.84 Mn |
| Sep 30, 2021 | -2.98 Mn |
| Jun 30, 2021 | -3.51 Mn |